Inge M. Van Der Sluis-Van Der Pluijm

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Immunoglobulin Depletion and Recovery Following Blinatumomab in Infants With KMT2A-Rearranged ALL.

Journal: Pediatric blood & cancer

Published: June 01, 2026

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial.

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial.

Journal: HemaSphere

Published: May 06, 2026

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus.

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus.

Journal: Cancer

Published: April 02, 2026

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Journal: Clinical pharmacokinetics

Published: February 05, 2026

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

Inotuzumab ozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse (ITCC-059): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Haematology

Published: January 27, 2026

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Sustained Benefit of Blinatumomab in Infants With KMT2A-Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 08, 2026

Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.

Drivers of Methotrexate Polyglutamate Concentration in Erythrocytes: Insights from Immune-Mediated Inflammatory Diseases and Pediatric Acute Lymphoblastic Leukemia.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 11, 2025

Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.

Successful re-exposure to high-dose methotrexate after severely delayed methotrexate elimination and renal toxicity in children with acute lymphoblastic leukemia.

Journal: Haematologica

Published: November 24, 2025

Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.

Philadelphia chromosome-positive acute lymphoblastic leukaemia in children and adolescents: A changing treatment landscape and a methodological challenge.

Journal: British journal of haematology

Published: September 17, 2025

Two episodes of Ph+ acute leukemia with divergent Ig/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.

Two episodes of Ph+ acute leukemia with divergent Ig/TCR rearrangements in two patients with persistent BCR::ABL1 positivity: a 17-year follow-up.

Journal: Haematologica

Published: July 10, 2025

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia-A comprehensive review.

Journal: British journal of clinical pharmacology

Published: May 01, 2025

DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia.

DNA-incorporated thioguanine to detect potential non-adherence to maintenance therapy in acute lymphoblastic leukemia.

Journal: Cancer chemotherapy and pharmacology

Published: March 07, 2025

Showing 1-12 of 101

Last Updated: 09/26/2026